Key details on ISIS Pharmaceuticals (Ticker: ISIS)
- CUSIP: 464330109
- Is ISIS overvalued or undervalued? Run a discounted cash flow (DCF) valuation analysis on ISIS
Who owns ISIS Pharmaceuticals?
Is ISIS a good stock to own? Find out who bought ISIS Pharmaceuticals, who sold ISIS Pharmaceuticals (ISIS) stock, and who holds a large position in ISIS Pharmaceuticals.
|Fund Name||Number of Shares||Share Valuation||As Of|
|FMR||17.69M||$714.93M||Sept. 30, 2015|
|ClearBridge Advisors||9.59M||$610.35M||March 31, 2015|
|Vanguard||8.81M||$355.66M||Sept. 30, 2015|
|BAILLIE GIFFORD & CO||7.90M||$319.29M||Sept. 30, 2015|
|BB Biotech AG||6.63M||$268.18M||Sept. 30, 2015|
|Waddell & Reed Financial||5.77M||$233.24M||Sept. 30, 2015|
|Columbia Wanger Asset Management||5.08M||$71.52M||Sept. 30, 2012|
|Artisan Partners Limited Partnership||3.85M||$237.86M||Dec. 31, 2014|
|BlackRock Institutional Trust Company, N.A.||3.05M||$123.19M||Sept. 30, 2015|
|BlackRock Fund Advisors||2.79M||$112.89M||Sept. 30, 2015|
|T. Rowe Price Associates||2.68M||$165.36M||Dec. 31, 2014|
|SUSQUEHANNA INTERNATIONAL||2.60M||$100.91M||Sept. 30, 2014|
|STATE STREET CORPORATION||2.50M||$101.00M||Sept. 30, 2015|
|EQUITEC SPECIALISTS||2.39M||$2.39M||Dec. 31, 2014|
|Tocqueville Asset Management||2.26M||$23.63M||Dec. 31, 2012|
Who sold ISIS Pharmaceuticals?
|Fund Name||Date Sold||Number of Shares Sold||Share Valuation|
|Gail Mannix||March 31, 2011||2.39M||$21.59M|